[1]
Vamecq, J.; Bac, P.; Herrenknecht, C.; Maurois, P.; Delcourt, P.; Stables, J.P. Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore. J. Med. Chem., 2000, 43, 1311-1319.
[2]
Herrera, J.A.; Ward, C.S.; Pitcher, M.R.; Percy, A.K.; Skinner, S.; Kaufmann, W.E.; Glaze, D.G.; Wehrens, X.H.; Neul, J.L. Treatment of cardiac arrhythmias in a mouse model of Rett syndrome with Na+-channel-blocking antiepileptic drugs. Dis. Model. Mech., 2015, 8, 363-371.
[3]
Thenmozhiyal, J.C.; Wong, P.T.; Chui, W.K. Anticonvulsant activity of phenylmethylenehydantoins: A structure-activity relationship study. J. Med. Chem., 2004, 47, 1527-1535.
[4]
Jintao, H.; Hongbo, D.; Zhihong, X.; Jianping, L.; Mingan, W. Facile synthesis of 5-arylidene thiohydantoin by sequential sulfonylation/desulfination reaction. Int. J. Mol. Sci., 2013, 14, 12484-12495.
[5]
Marinova, P.; Marinov, M.; Kazakova, M.; Feodorova, Y.; Slavchev, A.; Blazheva, D.; Georgiev, D.; Penchev, P.; Sarafian, V.; Stoyanov, N. Study on the synthesis, characterization and bioactivities of 3-methyl-9′-fluorenespiro-5-hydantoin. Acta Chim. Slov., 2016, 63, 26-32.
[6]
Siegel, R.; Desantis, C.; Jemal, A. Colorectal cancer statistics, 2014. CA Cancer J. Clin., 2014, 64, 104-117.
[7]
Haraldsdottir, S.; Einarsdottir, H.M.; Smaradottir, A.; Gunnlaugsson, A.; Halfdanarson, T.R. Colorectal cancer-review. Laeknabladid, 2014, 100, 75-82.
[8]
Rajić, Z.; Zorc, B.; Raic-Malic, S.; Ester, K.; Kralj, M.; Pavelic, K.; Balzarini, J.; De Clercq, E.; Mintas, M. Hydantoin derivative of L- and D-amino acids: Synthesis and evaluation of their antiviral and antitumoral activity. Molecule, 2006, 11, 837-848.
[9]
Kavitha, C.V.; Nambiar, M.; Ananda Kumar, C.S.; Choudhary, B.; Muniyappa, K.; Rangappa, K.S.; Raghavan, S.C. Novel derivatives of spirohydantoin induce growth inhibition followed by apoptosis in leukemia cells. Biochem. Pharmacol., 2008, 77, 348-363.
[10]
Carmi, C.; Cavazzoni, A.; Zuliani, V.; Lodola, A.; Bordi, F.; Plazzi, P.V.; Mor, M. 5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity. Bioorg. Med. Chem. Lett., 2006, 16, 4021-4025.
[11]
Cavazzoni, A.; Alfieri, R.R.; Carmi, C.; Zuliani, V.; Galetti, M.; Fumarola, C.; Frazzi, R.; Bonelli, M.; Bordi, F.; Lodola, A.; Mor, M.; Petronini, P.G. Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol. Cancer Ther., 2008, 7, 361-370.
[12]
Kumar, C.S.A.; Prasad, S.B.; Vinaya, K.; Chandrappa, S.; Thimmegowda, N.R.; Ranganatham, S.R.; Swarup, S.; Rangappa, K.S. Synthesis and antiproliferative activity of substituted diazaspiro hydantoins: A structure-activity relationship study. Invest. New Drugs, 2009, 27, 131-139.
[13]
Cano, I.; Selivanov, V.; Gomez-Cabrero, D.; Tegnér, J.; Roca, J.; Wagner, P.D.; Cascante, M. Oxygen pathway modeling estimates high reactive oxygen species production above the highest permanent human habitation. PLoS One, 2014, 9(11)e111068
[14]
Waris, G.; Ahsan, H. Reactive oxygen species: Role in the development of cancer and various chronic conditions. J. Carcinog., 2006, 5, 14.
[15]
Jie, L.; Wuliji, O.; Wei, L.; Zhi-Gang, J.; Ghanbari, H.A. Oxidative stress and neurodegenerative disorders. Int. J. Mol. Sci., 2013, 14, 24438-24475.
[16]
Naziroglu, M. Role of melatonin on calcium signaling and mitochondrial oxidative stress in epilepsy: Focus on TRP channels. Turk. J. Biol., 2015, 39, 813-821.
[17]
Liou, G.Y.; Storz, P. Reactive oxygen species in cancer. Free Radic. Res., 2010, 44, 479-496.
[18]
Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov., 2009, 8, 579-591.
[19]
Behrend, L.; Henderson, G.; Zwacka, R.M. Reactive oxygen species in oncogenic transformation. Biochem. Soc. Trans., 2003, 31(Pt 6), 1441-1444.
[20]
Trišović, N.; Božić, B.; Obradović, A.; Stefanović, O.; Marković, S.; Čomić, L.J.; Božić, B.; Ušćumlić, G. Structure-activity relationships of 3-substituted-5,5-diphenylhydantoins as potential antiproliferative and antimicrobial agents. J. Serb. Chem. Soc., 2011, 76, 1597-1606.
[21]
Obradović, A.; Žižić, J.; Trišović, N.; Božić, B.; Ušćumlić, G.; Božić, B.; Marković, S. Evaluation of anti-oxidative effects of twelve 3-substituted-5,5-diphenylhydantoins on human colon cancer cell line HCT-116. Turk. J. Biol., 2013, 37, 741-747.
[22]
Gupta, G.P. Massagué, J. Cancer metastasis: Building a framework. Cell, 2006, 127, 679-695.
[23]
Bucherer, H.T.; Lieb, V.A. Über die bildung substituierter hydantoine aus aldehyden und ketonen. synthese von hydantoinen. J. Prakt. Chem., 1934, 5, 141.
[24]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation andcytotoxicity assays. J. Immunol. Methods, 1983, 65, 55-63.
[25]
Shounan, Y.; Feng, X.; O’Connell, P.J. Apoptosis detection by annexin V binding: A novel method for the quantitation of cell-mediated cytotoxicity. J. Immunol. Methods, 1998, 217, 61-70.
[26]
Auclair, C.; Voisin, E. Nitroblue tetrazolium reduction, in Greenwald,
R. A. (Eds.), Handbook of Methods for Oxygen Radical Research,
BokaRaton, CRC Press. , 1985; pp. 123-132.
[27]
Pick, E.; Keisari, Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J. Immunol. Methods, 1980, 38, 161-170.
[28]
Baker, M.A.; Cerniglia, G.J.; Zaman, A. Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal. Biochem., 1990, 190, 360-365.
[29]
Griess, P. Comments on the treatise of the H.H. Weselky and Benedikt Ueber some azo compounds. Rep. German Chem. Soc., 1879, 12, 426-428.
[30]
Chen, H.C. Boyden chamber assay. Methods Mol. Biol., 2005, 294, 15-22.
[31]
Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 1987, 162, 156-159.
[32]
Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Method, 2001, 25, 402-408.
[33]
Cheeseman, K.; Rouleau, E.; Vannier, A.; Thomas, A.; Briaux, A.; Lefol, C.; Walrafen, P.; Bensimon, A.; Lidereau, R.; Conseiller, E.; Ceppi, M. A diagnostic genetic test for the physical mapping of germline rearrangements in the susceptibility breast cancer genes BRCA1 and BRCA2. Hum. Mutat., 2012, 33, 998-1009.
[34]
Hassan, M.; Watari, H.; Abu Almaaty, A.; Ohba, Y.; Sakuragi, N. Apoptosis and molecular targeting therapy in cancer. BioMed Res. Int., 2014, 2014150845
[35]
Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 2007, 39, 44-84.
[36]
López-Lázaro, M. Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett., 2007, 252, 1-8.
[37]
Sak, K. Chemotherapy and dietary phytochemical agents. Chemother. Res. Pract., 2012, 2012282570
[38]
Cook, T.; Wang, Z.; Alber, S.; Liu, K.; Watkins, S.C.; Vodovotz, Y.; Billiar, T.R.; Blumberg, D. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res., 2004, 64, 8015-8021.
[39]
Zhang, R.; Ma, A.; Urbanski, S.J.; McCafferty, D.M. Induction of inducible nitric oxidesynthase: a protective mechanism in colitis-induced adenocarcinoma. Carcinogenesis, 2007, 28, 1122-113.
[40]
Gupta, S.C.; Hevia, D.; Patchva, S.; Park, B.; Koh, W.; Aggarwal, B.B. Upsides and downsides of reactive oxygen species for cancer: The roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid. Redox Signal., 2012, 16, 1295-1322.
[41]
Sobolewski, C.; Cerella, C.; Dicato, M.; Ghibelli, L.; Diederich, M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int. J. Cell Biol., 2010, 2010215158
[42]
Mc Donnell, S.; Chaudhry, V.; Mansilla-Soto, J.; Zeng, Z.S.; Shu, W.P.; Guillem, J.G. Metastatic and non-metastatic colorectal cancer (CRC) cells induce host metalloproteinase production in vivo. Clin. Exp. Metastasis, 1999, 17, 341-349.
[43]
Basappa; Kumar, C.S.A.; Nanjunda Swamy, S.; Sugahara, K.; Rangappa, K.S. Anti-tumor and anti-angiogenic activity of novel hydantoin derivatives: Inhibition of VEGF secretion in liver metastatic osteosarcoma cells. Bioorg. Med. Chem., 2009, 17, 4928-4934.
[44]
Kumar, C.S.A.; Veeresh, B.; Ramesha, K.C.; Raj, C.S.A.; Mahadevaiah, K.M.; Prasad, S.B.B. Synthesis and evaluation of novel diazaspiro hydantoins as potential anticonvulsants. Cent. Nerv. Syst. Agents Med. Chem., 2017, 17, 201-208.
[45]
Jansen, M.; Potschka, H.; Brandt, C.; Löscher, W.; Dannhardt, G. Hydantoin-substituted 4,6-dichloroindole-2-carboxylic acids as ligands with high affinity for the glycine binding site of the NMDA receptor. J. Med. Chem., 2003, 46, 64-73.
[46]
Liu, H.; Liu, X.; Zhang, C.; Zhu, H.; Xu, Q.; Bu, Y.; Lei, Y. Redox imbalance in the development of colorectal cancer. J. Cancer, 2017, 8, 1586-1597.
[47]
Wu, W.S. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev., 2006, 25, 695-705.
[48]
Traverso, N.; Ricciarelli, R.; Nitti, M.; Marengo, B.; Furfaro, A.L.; Pronzato, M.A.; Marinari, U.M.; Domenicotti, C. Role of glutathione in cancer progression and chemoresistance. Oxid. Med. Cell. Longev., 2013, 2013972913
[49]
Shizhong, Z.; Fu, Y.; Anping, C. De novo synthesis of glutathione is a prerequisite for curcumin to inhibit HSC activation. Free Radic. Biol. Med., 2007, 43, 444-453.
[50]
Majid, A.S.; Yin, Z.Q.; Ji, D. Sulphur antioxidants inhibit oxidative stress induced retinal ganglion cell death by scavenging reactive oxygen species but influence Nuclear factor (erythroid-derived 2)-like 2 signalling pathway differently. Biol. Pharm. Bull., 2013, 36, 1095-1110.
[51]
Liu, Q.; Chan, S.T.; Mahendran, R. Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis, 2003, 24, 637-642.
[52]
Rigas, B.; Williams, J.L. NO-donating NSAIDs and cancer: An overview with a note on whether NO is required for their action. Nitric Oxide, 2008, 19, 199-204.
[53]
Gomez-Monterrey, I.; Santelli, G.; Campiglia, P.; Califano, D.; Falasconi, F.; Pisano, C.; Vesci, L.; Lama, T.; Grieco, P.; Novellino, E. Synthesis and cytotoxic evaluation of novel spirohydantoin derivatives of the dihydrothieno[2,3-b]naphtho-4,9-dione system. J. Med. Chem., 2005, 48, 1152-1157.
[54]
Shin, S.W.; Seo, C.Y.; Han, H.; Han, J.Y.; Jeong, J.S.; Kwak, J.Y.; Park, J.I. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin. Cancer Res., 2009, 15, 5414-5425.
[55]
Granados-Principal, S.; Liu, Y.; Guevara, M.L.; Blanco, E.; Choi, D.S.; Qian, W.; Patel, T.; Rodriguez, A.A.; Cusimano, J.; Weiss, H.L.; Zhao, H.; Landis, M.D.; Dave, B.; Gross, S.S.; Chang, J.C. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Res., 2015, 17, 25.
[56]
Kim, P.K.; Zamora, R.; Petrosko, P.; Billiar, T.R. The regulatory role of nitric oxide in apoptosis. Int. Immunopharmacol., 2001, 1, 1421-1441.
[57]
Bove, P.F.; Hristova, M.; Wesley, U.V.; Olson, N.; Lounsbury, K.M.; van der Vliet, A. Inflammatory levels of nitric oxide inhibit airway epithelial cell migration by inhibition of the kinase ERK1/2 and activation of hypoxia-inducible factor-1 alpha. J. Biol. Chem., 2008, 283(26), 17919-17928.
[58]
Liu, B.; Qu, L.; Yan, S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int., 2015, 15, 106.
[59]
Pérez-Sala, D.; Lamas, S. Regulation of cyclooxygenase-2 expression by nitric oxide in cells. Antioxid. Redox Signal., 2001, 3(2), 231-248.
[60]
Weinberg, J.B. Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. Immunol. Res., 2000, 22(2-3), 319-341.
[61]
Kessenbrock, K.; Wang, C.Y.; Werb, Z. Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol., 2015, 44-46, 184-190.
[62]
Said, A.H.; Raufman, J.; Xie, G. The role of matrix metalloproteinases in colorectal cancer. Cancers , 2014, 6, 366-375.
43
1